Maxim Group Forecasts Strong Price Appreciation for Zevra Therapeutics (NASDAQ:ZVRA) Stock

Zevra Therapeutics (NASDAQ:ZVRA) had its target price hoisted by stock analysts at Maxim Group from $25.00 to $35.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Maxim Group’s price target points to a potential upside of 156.49% from the company’s current price.

Other equities analysts also recently issued research reports about the stock. HC Wainwright restated a “buy” rating on shares of Zevra Therapeutics in a research note on Tuesday. Citizens Jmp boosted their price target on Zevra Therapeutics from $18.00 to $25.00 and gave the company a “market outperform” rating in a report on Tuesday. Cantor Fitzgerald boosted their price objective on shares of Zevra Therapeutics from $24.00 to $34.00 and gave the stock an “overweight” rating in a research note on Monday. Wall Street Zen cut shares of Zevra Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Canaccord Genuity Group lifted their price target on Zevra Therapeutics from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Tuesday. Eight investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $29.29.

Zevra Therapeutics Trading Down 0.1%

ZVRA stock traded down $0.01 on Wednesday, hitting $13.65. The company had a trading volume of 2,011,065 shares, compared to its average volume of 1,287,749. The stock has a market cap of $806.75 million, a price-to-earnings ratio of 6.87 and a beta of 0.91. Zevra Therapeutics has a 12-month low of $7.16 and a 12-month high of $14.27. The stock’s 50-day simple moving average is $10.46 and its 200 day simple moving average is $9.42.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.12. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%.The business had revenue of $36.22 million during the quarter, compared to the consensus estimate of $31.96 million. Research analysts forecast that Zevra Therapeutics will post 0.56 earnings per share for the current year.

Institutional Trading of Zevra Therapeutics

A number of hedge funds have recently bought and sold shares of ZVRA. Quantinno Capital Management LP increased its stake in shares of Zevra Therapeutics by 114.1% in the first quarter. Quantinno Capital Management LP now owns 32,022 shares of the company’s stock worth $298,000 after buying an additional 17,065 shares during the period. Dimensional Fund Advisors LP lifted its position in Zevra Therapeutics by 259.2% during the first quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock valued at $5,168,000 after buying an additional 400,336 shares during the period. AIGH Capital Management LLC purchased a new stake in shares of Zevra Therapeutics in the first quarter worth $11,184,000. Simplify Asset Management Inc. lifted its position in Zevra Therapeutics by 137.5% in the 1st quarter. Simplify Asset Management Inc. now owns 100,630 shares of the company’s stock valued at $938,000 after acquiring an additional 58,265 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its stake in Zevra Therapeutics by 16.7% during the 1st quarter. Janney Montgomery Scott LLC now owns 236,834 shares of the company’s stock valued at $2,207,000 after acquiring an additional 33,951 shares during the period. 35.03% of the stock is currently owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.